Tricida is a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, Veverimer (also known as TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis by binding and removing acid from the gastrointestinal (GI) tract. Veverimer is a non-absorbed, low-swelling, spherical polymer. It is a single, high molecular weight, crosslinked polyamine molecule. Veverimer is designed to specifically bind and remove hydrochloric acid from the GI tract. Acid binding and removal from the GI tract is an approach to treating metabolic acidosis without introducing deleterious counterions or metals. The TCDA stock yearly return is shown above.
The yearly return on the TCDA stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the TCDA annual return calculation with any dividends reinvested as applicable (on ex-dates).
|